Bispecific Antibody Research Update: Epcoritamab Receives FDA Priority Review
Bispecific antibodies, with two binding sites directed at two different antigens or two different epitopes on the same antigen, have shown some superiority in clinical therapeutic effects when compared with monoclonal antibodies,Read More…